I’m going to add that data very quickly to our current data sets and as we go forward with some of our partnering discussions.
Kaveri Pohlman: Thank you. That’s very helpful.
Operator: And your next question comes from the line of Kelly Shi from Jefferies. Your line is open.
Jay Short: Hello?
Operator: Kelly Shi, you might be on mute.
Dev Prasad: Hello? Can you hear me?
Jay Short: Now, we can.
Dev Prasad: Hi. This is Dev on for Kelly. And I have a question on 3021. Do you plan to share a non-small cell lung cancer data that you generated? And if you can share any insight that you can draw from the data, such as patient baseline or expression, which contributed to lower responses. Also for CTLA-4, can you set the expectation on data details, which a special number or dose level we should expect at R&D Day? Thank you.
Jay Short: Yes. We will definitely share the data on non-small cell lung cancer data. We’re going to move that to a meeting. We may also include data from the more frequent dosing with some of the other indications like head and neck cancer and melanoma. So we’ll be looking for an upcoming meeting on that. It’s still quite possible that because we saw responses in line, I’ll remind everyone in Phase I. But what we basically show that we’re not driving responses with the Q2W level. We’re also seeing responses with 2Q3W in head and back, but we — so we think that potential to go to a higher dose. But as part of our prioritization process, which is — has to factor in a very encouraging data out of the actual lung data. And we decided that it was best to prioritize AXL lung for that particular indication, while we continue to advance melanoma and head and neck, especially given the very high unmet need in those particular indications.
So we will give it and we’ll have quite a bit more data that we’ll be putting together for that release. With respect to CTLA-4, we will — we’re on track to give quite a bit of detail on our Phase I dose escalation, and we’ll be giving an update on the Phase II results that suffice it to say that the fact that we’ve already kicked off Phase II and that we have our first patient in and then Phase II that we think that it’s heading in a very good direction. And I’ll remind you that we’ve been studying patients that are known to be responsive to CTLA-4 was a basket of eight different indications that include things like melanoma and non-small cell lung cancer. So we’ll be discussing all of that in December. And so I just invite everyone on December 13th for the R&D day.
So we can give you a lot more detail around those studies.
Dev Prasad: Thank you taking our question.
Operator: [Operator Instructions] Your next question comes from the line of Arthur He from H.C. Wainwright. Your line is open.
Arthur He: Hey, good afternoon, Jay, Rick, Sheri and Eric. Thanks for taking my question. So I just wanted to push the envelope a little bit further on the 3011. These 33.3% ORR is that also including both the Q2W and the more intensive dose regimen or it’s only for the Q2W?
Jay Short: Only Q2W, we haven’t reported out on any more frequent dosing at.
Arthur He: Okay. Thanks for that. And then regarding to the [Technical Difficulty] program. For the ROR2 neck and melanoma patients, which showed a response, is that patient is in the Phase II study? Or it’s from the Phase I study? Could you remind that?
Jay Short: For head and neck, you mean?
Arthur He: No, for the melanoma, I believe.
Jay Short: For melanoma, we have two — excuse me we have one response from Phase I that’s included, and we have three responses from Phase II.
Arthur He: Okay. And so far, so you said you completed enrollment. So how many total patients we could expect the next data update?
Jay Short: Well, I don’t know — I don’t know what the evaluable patients will be, but we had targeted 20 patients. So we’ll see where we go on that, and we’ve reported on eight evaluable patients today, where we saw four responses out of eight and two with a stable disease; and two with progressive disease. So quite encouraging at this stage.
Arthur He: Got you. So my last question is for the 3182 your bispecific candidate for the EpCAM. So could you give us more color about the enrollment status for that trial?
Jay Short: I think it’s going well. I mean, it takes about a month, plus or minus a week to kind of get from patient to patient. So I think we’re on track here and continue to dose escalate. And I think it’s early, but all good so far. And this is a particularly interesting drug. And I get why — I would be asking the same question Arthur that you are because this is one of those pan-cancer opportunities with very high selectivity with a very potent mechanism that is enabled by CABS with this T-cell recruiting capability. And so we’re very eager to push it along. So it’s going to move quickly, and we’ll have a lot more to talk about it, and we have only seen positive things so far.
Arthur He: Awesome. Thanks for taking all my question and congrats on the program. Talk to you soon.
Jay Short: Thank you. Look forward to it.
